401 results about "SCC - Squamous cell carcinoma" patented technology

The present disclosure describes methods and compositions for diagnosing or predicting likelihood of a OSCC recurrence in a subject having undergone OSCC resection comprising: a) determining an expression level of one or more biomarkers selected from Table 4, 5 and / or 7, optionally MMP1, COL4A1, THBS2 and / or P4HA2 in a test sample from the subject, the one or more biomarkers comprising at least one of THBS2 and P4HA2, and b) comparing the expression level of the one or more biomarkers with a control, wherein a difference or a similarity in the expression level of the one or more biomarkers between the test sample and the control is used to diagnose or predict the likelihood of OSCC recurrence in the subject In particular, the present disclosure describes methods and compositions using a four-gene biomarker signature that can predict recurrence of oral squamous cell carcinoma in subjects that have histologically normal surgical resection margins.

The invention belongs to the field of drug synthesis and in particular relates to a series of novel peptide boric acids as well as an ester compound or pharmaceutical salt thereof, and a preparation method and application of the peptide boric acids as well as the ester compound or pharmaceutical salt thereof in pharmacodynamics. A structure of the peptide boric acid and the ester compound or pharmaceutical salt thereof is shown in a formula I (described in the specification). The compound provided by the invention can be used for preparing a proteasome inhibitor and can further be used for treating solid tumours and blood tumours, wherein the solid tumours are selected from non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous carcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, gastrointestinal stromal tumor, nasopharynx cancer and leukemia; and the blood tumours are selected from multiple myeloma, mantle cell lymphoma and histiocytic lymphoma.

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt / Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt / Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.

The invention discloses an OSCC (oral squamous cell carcinoma) biomarker and an application thereof. The biomarker is XIRP2, an experiment proves that an XIRP2 gene expresses up regulation in OSCC tissue, and the silent XIRP2 gene can reduce transcription and translation of the gene to inhibit excessive proliferation of OSCC cells. The invention provides the application of the gene or an expression product of the gene in diagnosis and treatment of OSCC.

The invention provides a primary cell culture medium for culturing primary esophageal squamous carcinoma epithelial cells and containing a combination of an MST1 / 2 kinase inhibitor and a ROCK kinase inhibitor, and a culture method using the primary cell culture medium. According to the culture method, the primary cells are cultured on a culture vessel coated with extracellular matrigel by using the primary cell culture medium, so that the primary cells are rapidly proliferated. The cell model obtained by the primary cell culture medium and the primary cell culture method can be used for evaluating and screening curative effects of medicines.

The invention discloses a serum protein marker for early screening and diagnosis of esophageal squamous carcinoma, and belongs to the field of biomedical technology. The serum protein marker is any one or a combination of two or more of proteins encoded by P53, GNA11, GNAS, PTEN, ACVR1B, FBXW7, EGFR, PDGFRA, SRSF2, MEN1, DAXX or CASP8 genes. Based on the role played by cancer driving genes in tumorigenesis and development, a human protein chip encoded by 138 cancer driving genes is customized, the human protein chip contains 180 human-derived recombinant proteins for screening out potential markers capable of diagnosing caners or other markers capable of characterizing cancers, early detection serum markers of the esophageal squamous carcinoma are primarily screened out by the protein chip, and then are verified by an ELISA indirect method experiment, a group of joint serum protein markers of esophageal squamous carcinoma for the early screening and diagnosis of the esophageal squamouscarcinoma is screened out at last for assisting the clinical diagnosis of the esophageal squamous carcinoma, so that the serum protein marker has better reference value.

The invention aims to provide a reagent capable of detecting the expression condition of a target protein in a paraffin-embedded tissue, and particularly provides a kit used for evaluating the prognosis information of a patient suffering from the esophageal squamous cell carcinoma. The kit comprises antibodies of the three target proteins, namely Annexin II, Kindlin-2 and Myosin-9, and further comprises goat serum, 0.01 M citrate repair liquid, 3% H2O2, a Polymer reinforcing agent, a Polymer, a DAB color reagent and a PBS solution. The kit can be used for evaluating the prognosis of the patient; compared with the international TNM staging, the kit is simpler and easier to use, and higher in both sensitivity and specificity, and is more suitable for the prognosis evaluation of Chinese suffering from the esophageal squamous cell carcinoma.

The invention discloses an anti-tumor combination and the application thereof; the anti-tumor combination which includes effective dose of platinum-based chemotherapy and AKT inhibitor and / or p70S6K1 inhibitor has the function of inhibiting the drug resistance of the tumor to the platinum-based chemotherapy, improves the effects of anti-tumor drugs, and can be used for preparing drugs that can resist various tumors, such as lung cancer, ovarian cancer, prostate cancer, breast cancer, stomach cancer, nasopharyngeal cancer, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer, osteosarcoma, etc.

The invention relates to an esophageal squamous cell carcinoma autoantibody molecular marker model and an application thereof. The molecular model mainly comprises an ALDOA autoantibody, an ENO1 autoantibody, a p53 autoantibody, and an NY-ESO-1 autoantibody, and can be used for preparing a kit for distinguishing esophageal squamous carcinoma patients and healthy medical examiners. The kit for detecting esophageal squamous cell carcinoma patients mainly comprises recombinant ALDOAD protein, recombinant ENO1 protein, recombinant p53 protein, and recombinant NY-ESO-1 protein. According to the esophageal squamous cell carcinoma autoantibody molecular marker model and the application thereof, the ENO1 autoantibody is found to be elevated in serum level in the esophageal squamous carcinoma patients for the first time, and is jointly detected with the ALDOA autoantibody, the p53 autoantibody, and the NY-ESO-1 autoantibody for distinguishing the esophageal squamous cell carcinoma patients andthe healthy medical examiners, and has a better distinguishing effect than a single index detection; and in addition, the detection method adopted by the invention is an enzyme-linked immunosorbent assay indirect method, is simple and convenient to implement, has good sensitivity and specificity, and is a method which is mature and reliable and can be widely used in base layer hospitals.

The invention belongs to the field of prognosis estimation and canceration risk prediction on clinic of molecular biology, and particularly relates to application of a molecule of a detection ANO1 protein in the preparation of a kit or a detection agent for the prognosis estimation and precancerous disease progression risk prediction of esophageal squamous carcinoma. The molecule expressed by the detection ANO1 protein can be a nucleic acid, a protein or a compound, thus showing that the ANO1 protein can be used as a molecular marker for the prognosis estimation and precancerous disease progression risk prediction of the esophageal squamous carcinoma.

The invention belongs to the technical field of medical image processing, and particularly relates to a cancer lesion detection and diagnosis system for early esophageal squamous cell carcinoma of a narrow-band endoscopic image. The system comprises a feature extraction backbone network, a feature pyramid, a region candidate network, a region of interest pooling unit and a cancer focus classification network, and a system for visualization on a narrow-band imaging endoscope image. The backbone network is used for extracting a feature map of an input image; the feature pyramid is used for fusing features of different scales; the region candidate network proposes a possible lesion region; the region of interest pooling unit pools the features to a suspected lesion area; the cancer lesion classification network classifies the cancer lesions; and finally, a narrow-band imaging endoscopic image is visualised, and frame selection marking is carried out on the cancer lesions by using different colors. The image of the narrow-band imaging endoscope is input into the network model, the cancer focus of the early esophageal squamous cell carcinoma existing in the image is detected and diagnosed, the diagnosis efficiency can be effectively improved, and a doctor is assisted in obtaining higher diagnosis precision.

The invention discloses a kit used for aided prediction on postoperative survival time of esophageal squamous cell carcinoma (ESCC) patients. The kit comprises a substance used for detecting lncRNA 1 expression quantity, a substance used for detecting lncRNA 2 expression quantity, and a substance used for detecting lncRNA 3 expression quantity; the sequence of lncRNA 1 is represented by sequence 1 in a sequence table; the sequence of lncRNA 2 is represented by sequence 2 in the sequence table; and the sequence of lncRNA 3 is represented by sequence 3 in the sequence table. A plurality of ESCC patients are investigated; expression characteristics of lncRNA in cancer tissue and near cancer normal tissue are analyzed; it is observed that expression profile of a plurality of lncRNA in cancer tissue is obviously different from that of near cancer normal tissue; a model is established based on three lncRNA relative expression quantity; and the model can be used for aided prediction on postoperative survival time of esophageal squamous cell carcinoma patients.

The invention provides microRNA (micro ribonucleic acid) for identification of subtypes of a lung cancer. The miroRNA is chosen from the following sequence: a) a sequence shown as SEQ ID No. n (sequence identification number), or b) microRNA complementary to the sequence shown as SEQ ID No. n, wherein the n is 2, 3, 4 or 7. The invention further provides an application of the microRNA and a reagent kit based on the microRNA. The invention further provides a set formed by the microRNA, an application of the set and a reagent kit based on the set. The miroRNA has the advantages that the microRNA can form two combinations, namely SEQ ID No.2 and SEQ ID No.7, as well as SEQ ID No.3 and SEQ ID No.4, which can be used to differentially diagnose the small cell lung cancer, non-small cell lung cancer, adenocarcinoma lung cancer and squamous cell lung cancer respectively; the diagnosis is high in speed, low in cost and accurate and reliable in result; and a significant basis is provided for performing precise targeted therapy on a patient with the lung cancer.

The invention discloses a kit for predicating lung cancer risk for high-risk groups among the China urban population on the basis of CT (computed tomography) images and biomarker spectrums. The kit comprises a reagent for measuring the expression quantity of serum protein spectrums of the following four biomarkers including pro-gastrin-releasing peptides, carcino-embryonic antigens, fragments of cytokeratin 19 and squamous-cell carcinoma antigens. The kit can be used for accurately predicating the lung cancer risk in combination of CT imageology parameters including nodule diameters, spicule signs and positions and other clinical indexes including age, the smoking history, the history of malignant tumor and genders.

The invention discloses a reagent for auxiliarily diagnosing lung cancer lymph node metastasis, comprising 8 antibodies which are used for detecting 8 protein markers which are MMP1 (matrix metalloproteinase-1), TIMP1 (tissue inhibitor of metalloproteinases metallopeptidase inhibitor 1), IQGAP1 (IQ motif containing GTPase activating protein 1), TPX2 (targeting protein for Xklp2), uPA (Urokinase-type plasminogen activator), Cathepsin-D, Fascin and pIgR / SC (polymeric immunoglobulin receptor / secretory component). By adopting the 8 antibodies and an immunohistochemical staining result, lung cancer lymph node metastasis can be auxiliarily diagnosed, and the reagent is expected to be used for the risk estimation of lung squamous cell cancer lymph node metastasis and the prognostic prediction. The reagent has high creditability, strong practicability and clinical use value based on the clinical routine immunohistochemical staining technology when the reagent is used for auxiliary diagnosis.

The invention provides a Lasso-based esophageal squamous cell carcinoma patient risk prediction column diagram model establishment method, which is used for evaluating the postoperative survival risk of esophageal squamous cell carcinoma patients. The method comprises the following steps: firstly, collecting clinical data of esophageal squamous cell carcinoma patients, analyzing the clinical data by utilizing single-factor Cox, Lasso and multi-factor Cox regression analysis methods to obtain important characteristic variables, and establishing probability prediction models with different characteristic dimensions; secondly, selecting a probability prediction model with better performance and establishing a postoperative risk prediction column diagram model of the esophageal squamous cell carcinoma patient; and finally, dividing the patients into a high-risk group and a low-risk group according to the postoperative risk prediction column diagram model of the esophageal squamous cell carcinoma patients, and verifying the reliability and effectiveness of model classification through a KM survival curve analysis method. According to the method, the postoperative survival risk of the esophageal squamous cell carcinoma patient can be accurately predicted, reference is better provided for treatment of the esophageal squamous cell carcinoma patient, and meanwhile the risk prediction cost is reduced.

The invention discloses an esophageal squamous carcinoma radical postoperative patient prognosis prediction model construction method and device, and the method comprises the steps: obtaining clinical diagnosis and treatment data and follow-up visit survival data, carrying out multi-factor Cox regression analysis on patient characteristic variables, tumor pathology characteristic variables, treatment condition variables and test index variables according to follow-up visit survival data, carrying out variable screening by utilizing a step-by-step back algorithm and an Akaike information criterion, and carrying out variable screening on the screened candidate variables again to obtain modeling variables; and performing multi-factor Cox regression analysis on modeling variables and interaction items of every two modeling variables to construct a prognosis prediction model of a patient after the esophageal squamous carcinoma radical operation, wherein the prediction variables comprise age, gender, tumor primary position, T stage, lymph node detection number, tumor size, preoperative hemoglobin level and N stage treatment mode interaction items. According to the method, the prediction accuracy can be improved, the optimal benefit group of different treatment schemes is defined, and the prognosis evaluation precision of the esophageal squamous cell carcinoma is realized.

The invention discloses application of a pharmaceutical composition in preparation of a therapeutic drug for a tumor insensitive to PD-1 antibody immunotherapy, and particularly relates to applicationof a PD-1 antibody combined LY2874455 in preparation of a drug for treating a chromosome 11q13.3 segment amplified tumor. Advanced solid tumors include esophageal squamous carcinoma, colorectal cancer, melanoma, head and neck squamous carcinoma or bladder cancer and the like. The anti-PD-1 antibody and LY2874455 combined medication scheme can be used for the tumor which is amplified in the chromosome 11q13.3 segment and is insensitive to PD-1 antibody immunotherapy, and compared with single-drug treatment, tumor growth is remarkably inhibited, so that a patient ineffective to the PD-1 antibody can benefit from the combined therapy.

Disclosed is a method for preventing the development of head and neck squamous cell carcinoma (HNSCC) in a mammal who is at risk for developing such carcinoma comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor to the mammal. An example of such inhibitor is rapamycin.

The invention belongs to the technical field of medicines and relates to a thienothio compound and an application thereof. A thienothiapyran compound comprises derivatives and pharmaceutically applicable salt of the thienothiapyran compound, and has a structural formula; the thienothiapyran compound and the pharmaceutically applicable acid addition salt of the thienothiapyran compound can be combined with conventional drugs or are individually used as epidermal growth factor tyrosine kinase inhibitors for treating related diseases of epidermal growth factor receptor signaling dysregulation, such as small cell lung cancers, squama cancers, glandular cancers, large cell cancers, colorectal cancers, breast cancers, ovarian cancers, renal cell cancers and bronchial asthma.

The invention discloses an application of a biomarker RP11-54A9.1 in prediction of oral squamous cell carcinoma and treatment of the oral squamous cell carcinoma. In the invention, a gene RP11-54A9.1,differentially expressed in oral squamous cell carcinoma, is studied, and an influence of the differentially expressed gene RP11-54A9.1 on the oral squamous cell carcinoma is explored through a further cell experiment, it is found that proliferation and migration capacity of oral squamous cell carcinoma cells can be remarkably reduced by inhibiting expression of RP11-54A9.1, and therefore a noveloral squamous cell carcinoma biomarker with molecular diagnosis, prognosis prediction and targeted therapy is provided clinically.

The invention discloses application of a reagent for detecting and targeting a biomarker in oral squamous cell carcinoma. The biomarker is lncRNA LINC01679. The invention discloses application of theLINC01679 in preparation of a product for diagnosing the oral squamous cell carcinoma and the product for diagnosing the oral squamous cell carcinoma. Meanwhile, the invention discloses application ofthe LINC01679 in preparation of a pharmaceutical composition for treating the oral squamous cell carcinoma and the pharmaceutical composition for treating the oral squamous cell carcinoma.

The invention relates to an early molecular diagnosis marker for esophageal squamous cell carcinoma and an application of the marker. Parts of patients suffering from early esophageal squamous carcinoma may lose the best treatment opportunity due to indefinite diagnosis caused by the existing diagnostic technique level of the esophageal squamous cell carcinoma, more accurate indexes are required for supplement, and a molecular biology method for researching and identifying effective molecule markers is a key means for assisting existing clinical diagnosis, clinical intervention guide and precancerous warning. The provided early molecular diagnosis marker mir-1277 for esophageal squamous cell carcinoma and mature miRNA provide a potential basis for accurate diagnosis of clinical esophageal squamous cell carcinoma and have important actual application value.

The invention relates to novel application of small molecule metabolites, namely hypoxanthine, 2-ketoisocaproic acid, glutamic acid and aspartic acid, in a serum sample as combined markers in preparation of a kit for distinguishing patients with esophageal squamous carcinoma and esophageal epithelial atypical hyperplasia in subjects. The invention further relates to a kit for detecting patients with esophageal squamous cell carcinoma in subjects. The relative concentration of the combined markers in serum samples from the subjects is detected, the variables P of the combined marker are calculated based on a linear regression equation, and whether the subjects suffer from esophageal squamous cell carcinoma or not is judged based on a determined threshold value. The kit can realize high-sensitivity and high-efficiency detection of several metabolites involved in the invention, and has the advantages of low detection cost and good repeatability. The kit can be applied to clinical auxiliary diagnosis of the esophageal squamous cell carcinoma, has the advantages of high diagnosis sensitivity and capability of effectively distinguishing the esophageal squamous cell carcinoma from precancerous lesions, and has a relatively good application prospect.

The present invention provides a novel cancer marker that is useful in the diagnosis of urothelial cancer. The present invention uses ubiquilin 2 as a cancer marker for urothelial cancer (renal pelvis cancer, ureteral cancer, and bladder cancer). Detection of ubiquilin 2 in a urine sample allows easy and accurate diagnosis of a possibility of urothelial cancer. The present invention is also applicable to the diagnosis of squamous cancer (esophageal cancer, cervical cancer, etc.).

The invention belongs to the technical field of medical biology, and particularly discloses a marker hsa - circRNA6448-14 for diagnosis and prognosis prediction of esophageal squamous cell carcinoma.The hsa - circRNA6448-14 is highly expressed in esophageal squamous cell carcinoma tissues, and is expressed in para-carcinoma normal tissues. By detecting the expression level of hsa - circRNA6448-14in tissues, the esophageal squamous cell carcinoma can be subjected to diagnosis and prognosis prediction. The invention provides a new approach for diagnosis and prognosis prediction of the esophageal squamous cell carcinoma, and provides a reference basis for clinicians to diagnose esophageal squamous cell carcinoma and analyze conditions of the esophageal squamous cell carcinoma.

The present disclosure provides methods and systems for identifying and / or treating subjects having cancer, such as squamous cell carcinoma, who are more likely to respond to treatment with an ERK inhibitor.

The invention relates to a biomarker for typing non-small cell lung cancer, and application thereof, and belongs to the technical field of medical detection. The biomarker comprises at least five genes such as TP53, STK11, PTEN, NFE2L, KRAS and the like. When squamous cell carcinoma and adenocarcinoma in small cell carcinoma of lung are subjected to typing by utilizing the biomarker, the AUC of a typing diagnosis ROC curve is 0.700 when the at least five markers are used, the AUC of the typing diagnosis ROC curve is 0.734 when the number of the markers is further increased to 10, and the AUC can reach 0.786 when all the biomarkers are used, so that the biomarkers have excellent diagnosis capability.